PDCD1 and Hodgkins lymphoma: For patients ≥12 years of age with newly diagnosed stage III-IV classic Hodgkin lymphoma, a randomized phase 3 trial is evaluating immunotherapy (nivolumab, an anti-PD-1 antibody, versus brentuximab vedotin, an antibody-drug conjugate targeting CD30 on the surface of Hodgkin lymphoma cells) with standard combination chemotherapy followed by consolidative radiotherapy as clinically indicated [SWOG S1826, NCT03907488].